Wingspan Coverage Policy Has Broad Implications For Humanitarian Devices
This article was originally published in The Gray Sheet
Executive Summary
CMS' proposed coverage decision for Boston Scientific's Wingspan intracranial stent has stakeholders on edge about the precedent the agency could set in its first national decision for a humanitarian-use device
You may also be interested in...
Boston Sci’s Wingspan Gets Limited Nat’l Coverage; Broad HDE Policy Will Wait
Medicare will nationally cover intracranial stenting and angioplasty only in the controlled setting of FDA-cleared clinical trials, CMS says
Boston Sci’s Wingspan Gets Limited Nat’l Coverage; Broad HDE Policy Will Wait
Medicare will nationally cover intracranial stenting and angioplasty only in the controlled setting of FDA-cleared clinical trials, CMS says
Neurotechnology Interests Form New Trade Association To Lobby Congress
A newly formed trade association called the Neurotechnology Industry Organization (NIO) will seek greater government support for the development of therapies for brain and nervous system diseases